Cantargia (Q3 Review): Planning for a Pivotal Study of Nadunolimab - Redeye
Bildkälla: Stockfoto

Cantargia (Q3 Review): Planning for a Pivotal Study of Nadunolimab - Redeye

Redeye comments on Cantargia's third quarter report 2025. Cantargia is planning for a pivotal study in pancreatic cancer in 2026, pending the finalisation of the IL1RAp diagnostic and funding. We have therefore changed our valuation assumptions. A new bispecific antibody, CAN14, is being developed for immunological diseases. The next catalyst is the survival readout of TRIFOUR in TNBC scheduled for this year.

Redeye comments on Cantargia's third quarter report 2025. Cantargia is planning for a pivotal study in pancreatic cancer in 2026, pending the finalisation of the IL1RAp diagnostic and funding. We have therefore changed our valuation assumptions. A new bispecific antibody, CAN14, is being developed for immunological diseases. The next catalyst is the survival readout of TRIFOUR in TNBC scheduled for this year.
Börsvärldens nyhetsbrev